Abbott, GSK lead listed pharma to Rs11.6bn Q1 profit

Net sales hit Rs98.8 billion and gross margins widened, even as market value fell and Afghanistan exports stayed suspended, Topline Securities said.

Listed pharmaceutical sector profit after tax rose 11% year-on-year to Rs11.6 billion in 1QFY27.

Net sales reached Rs98.8 billion; gross margin improved to 43.7% from 41.9% a year earlier.

Market capitalisation fell 24% year-on-year to Rs505.2 billion as of 30 October 2026.

Abbott, GlaxoSmithKline, Searle and Haleon together drove a large share of sector sales.

Finance costs rose 22% to Rs1.2 billion while other income fell to Rs802 million.

Read the full story